Enveric Biosciences, Inc.
corporate_fare Company Profile
Enveric Biosciences, Inc. (NASDAQ:ENVB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for ENVB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for ENVB spans 10-Q, 8-K, 424B5, 424B3.
Recent high-impact activity:
- Enveric 10-Q: Going Concern Warning, $5.6M Cash, Material Weaknesses Disclosed
- Enveric Q2 10-Q: $3.0M Loss, Going Concern Warning, and $8.3M Cash
- Enveric Reports Q2 Loss of $3.0M, $8.3M Cash, and $6.5M in New Financing
- New Preclinical Data Reinforces Non-Hallucinogenic Profile of Enveric's Lead Candidate EB-003
- Enveric Biosciences Expands Highly Dilutive ATM Offering by $2.4M Amidst Going Concern Warning
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 19,617 shares in ENVB as of the October 30, 2026 settlement, a 49.3% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 15.4% of ENVB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for ENVB, detected from its recent SEC filings · based on capital-structure filings through 2026-06-09.
ATM Offering Expanded · Significant Prior Sales
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →